Background and Aims: MicroRNAs [miRNAs] have emerged as important regulators in inflammatory bowel disease [IBD]. This study investigated differential expression of miRNAs across clinical phenotypes in a well-characterized cohort of IBD patients and healthy controls [HCs]. Methods: A cohort of Crohn's disease [CD] and ulcerative colitis [UC] patients and HCs was prospectively accrued. Total RNA was extracted from peripheral blood mononuclear cells for all subjects. miRNA expression was measured using NanoString technologies. The subjects were stratified according to disease activity and location. Statistical significance was assessed per miRNA across outcomes and corrected for multiple testing. miRNA regulation of transcription of important results was confirmed in vitro by a dual luciferase reporter assay and autophagy function was evaluated using immunofluorescence imaging of LC3 puncta in HeLa cells. Results: In total, 120 subjects were enrolled. Seventy-four miRNAs were differentially expressed across CD, UC and HCs. Comparing quiescent CD [CDq] with HCs we found ten miRNAs upregulated in CDq. When comparing colonic CD [CCD] to UC, seven miRNAs were upregulated in CCD. The most differentially expressed miRNA in CCD vs UC was miR-874-3p, and we showed its possible utility as a biomarker of differential diagnosis. We showed miR-874-3p targets ATG16L1 and reduces its expression in vitro. An miR-874-3p mimic dysregulates autophagy by a reduction of LC3 in vitro. Conclusions: We identified unique miRNA signatures expressed in distinct IBD phenotypes. These associations highlight pathways dysregulated by aberrant miRNA expression, revealing possible mechanisms underlying the pathophysiology of IBD, but also suggest a cluster of miRNAs as readily accessible biomarkers to aid in differential diagnosis.
Introduction
Inflammatory bowel disease [IBD] encompasses a spectrum of chronic, heterogenetic, relapsing disorders of the gastrointestinal tract, the main types being ulcerative colitis [UC] and Crohn's disease [CD] . Although the exact cause of IBD is unknown, evidence suggests it is due to an aberrant immune response against a triggering environmental factor in a genetically susceptible individual. 1 Over half of patients with IBD will face a challenging disease course that can result in inability to work, hospitalization and surgery. 2 Clinical heterogeneity in IBD is defined by behaviour and extent of the gastrointestinal inflammation. Inflammation in UC is confined to the colorectum and is limited to the mucosa, whereas inflammation in CD can occur anywhere along the digestive tract [although it is primarily localized to the colon and ileum], typically appears patchy with skip lesions, and can be transmural.
The identification of over 200 susceptibility loci in IBD by genomewide association studies [GWAS] has highlighted pathways and factors mechanistically important in IBD, yet the success of functional associations of these risk loci to phenotypic expression in IBD has been modest. 3, 4 These GWAS-identified loci are typically in non-coding regions of the genome and may include several variants in linkage disequilibrium, 5 making causal interpretation a challenge. Therefore, investigating epigenetic or post-transcriptional regulation of susceptibility genes may provide insight into disease pathogenesis. Pursuant to this, microRNAs [miRNAs] are approximately 22-nucleotide noncoding RNAs that bind to complementary sequences in target messenger RNAs [mRNAs] causing mRNA degradation and/or translational repression. 6, 7 Canonically, miRNAs will bind to the 3′ untranslated region [3′UTR] of the target mRNA, but can also efficiently bind to the 5′UTR and coding region of the mRNA. 8, 9 Human miRNA profiling studies have identified unique signatures in blood and tissue from patients with distinct IBD clinical phenotypes. [10] [11] [12] [13] [14] [15] [16] [17] [18] Early work by Wu et al. 14 analysed miRNA expression in biopsies of a small cohort of patients with active CD compared to healthy control subjects, and found four miRNAs differentially expressed in the ileum of six patients with active Crohn's ileitis compared to 13 healthy controls, and five miRNAs differentially expressed in colonic tissue in five active Crohn's colitis patients compared to the healthy controls. Further studies found unique panels of miRNAs in blood and tissue distinguishing CD and UC in varying regimes of disease activity. 10, 13, 18 While miRNA profiling studies to date suggest aberrant miRNA expression in IBD as well as their potential use in differential diagnosis, most investigations are in small populations or in the case of larger, heterogeneous cohorts, the studies employ targeted analysis of a limited number of miRNAs, preventing the discovery of novel miRNA associations. Current differential expression studies thus have drawbacks due to their limited power or the restricted set of miRNAs analysed. This study aims to investigate the role of miRNAs as disease regulators and their potential as non-invasive diagnostic markers in peripheral blood mononuclear cells [PBMCs] , in a well-characterized, large IBD population and healthy controls.
Materials and Methods

Subject cohort
A cohort was prospectively accrued at Mount Sinai Hospital in Toronto, Canada, in a tertiary referral IBD centre following approval of the study by our institution's research ethics board [REB] . All subjects gave informed consent prior to the initial sample collection in compliance with REB study approval. Adult subjects with a diagnosis of CD or UC and healthy controls were included in this study. Demographic and clinical characteristics of the study cohort can be found in Table 1 . Continuous variables across outcome groups in Table 1 were compared with a two-tailed Welch's t test, and nominal variables were compared with Fisher-FreemanHalton tests. Full ileocolonoscopy was performed on each subject and the endoscopy report was reviewed and scored for clinical, histological and endoscopic activity. Expert IBD endoscopists used established clinical, endoscopic and histological criteria to make the diagnosis of CD or UC. These were confirmed through additional chart review. Patients who were pregnant, unable to give consent independently or for whom there was diagnostic uncertainty about their IBD were excluded, as were patients with known intercurrent infection. Asymptomatic individuals undergoing screening for colorectal carcinoma who had a normal colonoscopy showing no intestinal inflammation macroscopically at the time of endoscopy or microscopically on subsequent histology were recruited as healthy controls.
Baseline 
Total RNA extraction
PBMCs from PAXgene-preserved blood samples were isolated and total RNA was extracted using the PAXgene Blood miRNeasy Kit [Qiagen] following the manufacturer's protocol.
miRNA quantification
PBMC-derived total RNA samples that passed quality control were randomly allocated to one of ten batches of 12 samples per batch. Samples were prepared using the nCounter miRNA Sample Preparation Kit [Nanostring Technologies]. After overnight codeset hybridization as per the manufacturer's protocol [https://www. nanostring.com/download_file/305/3824], RNAs were processed using the nCounter Digital Analyzer, and analysed by nSolver software [v2.5; Nanostring Technologies]. NanoString's Human v3 miRNA Panel was the codeset used, and it contained six positive spike-in controls per lane. Raw counts were normalized using internal positive controls as well as reference [housekeeping] genes provided in the codeset as described in the nCounter gene expression data analysis guidelines [http://www.nanostring.com /applications/miRNA]. Background noise was assessed using eight negative control probes designed not to hybridize to any human target provided in the codeset as described in the software guidelines. The NanoString miRNA expression assay was performed at the Princess Margaret Genomics Centre [Toronto, ON, Canada].
Differential miRNA expression
Normalized miRNA counts were log2-transformed and corrected for batch effects using the package ComBat 20 in R 3.1.1. Differential 
Bioinformatic miRNA-mRNA target prediction
Predicted target mRNAs for the differentially expressed miRNAs were identified using the miRWalk version 2.0 software tool [http:// www.ma.uniheidelberg.de/apps/zmf/mirwalk/]. 24 Four databases of predicted target mRNAs were selected: miRanda, miRWalk, RNA22 and TargetScan. We selected potential targets that were identified by at least three out of four databases. One miRNA can putatively target thousands of mRNAs, 25 so to maintain relevance to this study we filtered all predicted targets to GWAS-identified CD risk-associated genes. 26, 27 Finally, we used unpublished RNAseq data from an ongoing blood transcriptomics study in our group 28 to identify mRNAs that were differentially expressed with inverse directionality to miRNA expression as further evidence of target repression. Specifically, a partially overlapping cohort of IBD and healthy subjects was phenotyped and stratified similarly to the cohort presented here for miRNA evaluation. Non-parametric Kruskal-Wallis tests assessed the mRNA differential expression of normalized and transformed mRNA counts across comparative outcome groups for each of the CD risk genes predicted to be targets of the differentially expressed miRNAs. Only mRNAs with inverse directionality to miRNA expression were reported, based on biological relevance. were normalized to Renilla RLUs to correct for differences in viability and transfection efficiency between replicates.
GO and KEGG pathway analysis
To validate not only that miR-874-3p represses autophagy related 16 like 1 [ATG16L1] in HeLa cells but also that overexpression of miR-874-3p inhibits autophagy, we performed immunofluorescence imaging of LC3 puncta. HeLa cells were grown on two, four-well chamber slides, transfected with either miR874-3p mimic, inhibitor or negative control miRNA or remained untransfected for 48 
Statistical analysis for functional validation experiments
A one-way ANOVA and Bonferroni post hoc test compared means among treatments in the DLR assay, while a two-way ANOVA and Bonferroni post hoc test compared means within and between treatment groups. All experiments were performed in independent triplicate. Data were analysed using GraphPad 7 [GraphPad Software]. A p-value < 0.05 was considered statistically significant.
Results
Subject demographic and clinical characteristics
The study cohort included 120 subjects, grouped into three broad clinical phenotypes: n = 35 CD, n = 46 UC and n = 39 healthy controls [HCs] . Baseline relevant characteristics across phenotypes and comparative outcome groups are summarized in Table 1 . The age at enrollment was significantly higher in the HC group compared to the UC and CD groups [p < 0.0001], which was expected because the HC group comprised asymptomatic individuals undergoing colon cancer screening. There was no significant difference in gender across the three groups. Medication use between CD and UC differed as well; a significantly higher number of CD subjects were on the immunosuppressant azathioprine [p = 0.01], and far more UC subjects were on 5-aminosalicylate [5-ASA] treatment compared to CD subjects [p < 0.0001]. Clinical and endoscopic activity scores were similar between the two IBD groups. The majority of the CD group had a diagnosis of ileocolonic disease [L3] , and the majority of the UC group had at least left-sided colonic disease [E2/E3]. Further analyses in this study involved stratifying the data based on disease location and activity into secondary outcome groups for pairwise comparisons. These subsequent comparative groups [ Table 1 ] were endoscopically quiescent CD [CDq, n = 10] vs HC, and colonic CD [CCD, n = 11] vs UC. Importantly, there were no significant differences in disease activity scores [clinical or endoscopic] or CRP levels between the CCD and UC groups, suggesting similar levels of inflammation.
miRNA expression in peripheral blood between CD, UC and control subjects
Comparison of miRNA expression between the primary outcome groups CD, UC and HC resulted in 74 differentially expressed miRNAs across the three groups after FDR correction [ Figure 1 ]. The differential expression for all probes is summarized in Supplementary  Table 2 . The miRNA expression in the CD group is visually distinct and generally upregulated compared to both the UC and the HC groups, while the UC and HC group appear more similar [ Figure 1 ]. Indeed, pairwise comparisons confirm CD driving differential expression across the three groups [Supplementary 
Differential expression of miRNAs between both active and quiescent CD subjects vs control subjects
We focused further on disease occurrence in the absence of active inflammation. We assessed differential miRNA expression between endoscopically quiescent CD subjects [CDq, Table 1 ] and HC, as well as active CD subjects [CDa, Table 1 ] and HC to identify miRNA expression profiles not confounded by inflammation. Summary statistics for all probes are in Supplementary Table 2. All significant differentially expressed probes from both CDa vs HC and CDq vs HC analyses are summarized in Figure 2 . In total, 24 probes were differentially expressed comparing CDq to HC and 37 probes were differentially expressed comparing CDa to HC, of which 14 probes were commonly differentially expressed in the two comparisons [ Figure 2 ]. All were upregulated in CD [ Figure 3 , Supplementary Table 2 ]. Examining miRNA profiles distinctly expressed in quiescent disease may reveal molecular phenotypes important in remission as well as disease susceptibility. We therefore chose to focus subsequent analyses on the ten miRNAs that were not significant in the CDa vs HC analysis and only significant in the CDq vs HC comparison, namely miR-4448, miR-548g-3p, miR-4536-5p, miR-30a-3p, miR-548q, miR-4461, miR-133a-3p, miR-597-5p, miR-619-3p and miR-644a [ Figure 2 , miRNAs in bold]. Figure 3 depicts the miRNA signature for the ten probes uniquely differentially expressed in CDq compared to HC. The most significantly differentially expressed of these is miR-4448 [FDR-adjusted p = 0.017].
Molecular signalling pathway enrichment analysis suggests dysregulation of TGF-beta signalling pathway through targeting of SMAD3 by miR-4448
We then sought to identify molecular signalling pathways of known importance in IBD potentially altered by the ten miRNAs uniquely differentially expressed in CDq vs HC. We used the publically available miRNA pathway analysis web server, mirPath v.3, to find statistically significant KEGG pathways containing putative targets of the input miRNAs. Table 2 details all KEGG pathways associated with predicted targets of the ten miRNAs in Figure 3 that passed FDR correction. The most significant pathway identified, which is also known to be important in IBD, [30] [31] [32] is the transforming growth factor beta [TGF-beta] signalling pathway [ Table 2 , in bold, p = 0.0001]. Eight of the ten miRNAs uniquely expressed in CDq vs HC putatively target a total of 23 genes in the TGF-beta signalling pathway [ Table 2 ]. The in silico gene targets and the corresponding miRNAs are summarized in Table 3 . Interestingly, miR-4448 is the miRNA most strongly associated with the Crohn's group in the CDq vs HC comparison [ Figure 3 ] and putatively targets mothers against decapentaplegic homolog 3 [SMAD3] [ Table 3 ], a CD-associated risk gene and critical component in the canonical TGF-beta signalling pathway. [33] [34] [35] [36] As a supplementary analysis, we utilized RNAseq data from the previously described ongoing study in our group which sequenced the whole blood transcriptomes of a large, partially overlapping cohort of CD, UC, HC and inflammatory bowel disease unclassified [IBDU] subjects. 28 This cohort contained eight CDq subjects and 46 HC subjects. Using a non-parametric test to assess differential expression of SMAD3 between the two groups, mRNA expression level of SMAD3 in the CDq group was significantly lower than in the HC group [ Supplementary Figure 2 , p = 0.02]. This suggests that higher expression of miR-4448 in CD subjects compared to HCs might reduce expression levels of the predicted SMAD3 target, resulting in a dysfunctional inflammatory response in individuals genetically susceptible to CD.
Differential expression of miRNAs in colonic CD vs UC
We then assessed differential expression of miRNAs in our cohort based on disease location. We compared miRNA expression levels in subjects diagnosed with CD where inflammation was limited to the colon [CCD, L2 subjects in Table 1 ] with UC subjects. Seven differentially expressed miRNAs emerged after correction for multiple testing, all upregulated in the CCD group [ Figure 4 ]: miR-874-3p, miR-933, miR-129-5p, miR-1909-3p, miR-212-3p, miR-885-5p and miR-619-3p. Summary statistics for all probes are given in Supplementary Table 2. miR classifying clinical phenotypes. In our supplementary analysis assessing miRNA differential expression across phenotypes controlling for total leukocyte count and lymphocyte to non-lymphocyte ratio in blood as covariates, we found no significant association between these covariates and differential expression of miR-874-3p [Supplementary Table 1 ]. An ROC curve was generated to assess the diagnostic performance of miR-874-3p in classifying CCD vs UC [ Figure 5 ]. The AUC for the ROC was 0.91, suggesting that miR-874-3p could be a biomarker in the differential diagnosis of CCD and UC.
Bioinformatic analysis identifies CD-associated risk genes as putative targets of miRNAs differentially expressed in CCD vs UC
We performed in silico target prediction analysis of the seven miRNAs significantly upregulated in the PBMCs of CCD subjects compared to UC subjects using the miRWalk 2.0 tool. 24 Table 4 summarizes the miRNA-mRNA pairs that remained significant and possessed the correct directionality after non-parametric testing. Notably, the one predicted target of the most differentially expressed miRNA, miR-874-3p, that survived our filtering process is ATG16L1. ATG16L1 is strongly associated with CD susceptibility, and a variant of this gene has been associated with impairment of xenophagy, a form of autophagy directed towards intracellular pathogens. 37 We therefore next performed a search of pathways more generally involved in autophagy that may be targeted by these seven miRNAs. Table 5 summarizes the gene ontology biological process [GO BP] pathways containing terms related to autophagy targeted by the miRNAs differentially expressed in CCD vs UC, as identified by miRWalk 2.0. The enrichment of GO pathways applied the hypergeometric test of significance, followed by Benjamini-Hochberg FDR correction on all possible pathways. For a list of all predicted pathways targeted by each of the seven miRNAs see Supplementary  Table 4a. Table 5 contains only the pathways containing the terms 'autophagy' or 'autophagic' or 'macroautophagy' identified by the miRWalk algorithm. Six of the seven miRNAs are predicted to target multiple genes involved in autophagy-associated pathways, and five of these miRNA-GO BP pathway associations were significant after FDR correction [ Table 5 ]. These five miRNAs that are predicted to target genes involved in autophagy are miR-619-3p, miR-874-3p, miR-212-3p, miR-885-3p and miR-933. A list of the specific predicted gene targets summarized with a total count in the 'No. of genes' column in Table 5 for each of the seven miRNAs within each GO BP pathway can be found in Supplementary Table 4b . All miRNAs predicted to target genes in GO BP pathways with the same search terms and the corresponding genes are summarized in Supplementary Table 4 . This pathway analysis suggests that our panel of aberrantly co-expressed miRNAs modifies the translation of many genes involved in autophagy other than the risk gene ATG16L1.
miR-874-3p binds to the 3′UTR of ATG16L1 and represses transcript expression
To experimentally confirm that miR-874-3p targets the 3′UTR of ATG16L1, we performed in vitro validation of the miR-874-3p and ATG16L1 interaction by DLR. The miR-874-3p mimic significantly reduces the expression of ATG16L1 [ Figure 6 , p = 0.0005]. There was no significant difference between the miR-874-3p inhibitor, scrambled negative control miRNA and vector-only control conditions. In comparison, the pEZX-MT06 control vector, which does not contain a 3′UTR, showed no significant difference between each of the treatments [ Figure 6 ]. This demonstrates repression of ATG16L1 by miR-874-3p in vitro.
Finally, to investigate the effect of miR-874-3p overexpression on autophagy, we performed immunofluorescence of LC3 puncta in rapamycin-treated and untreated transfected cells [ Supplementary Figure 3] . TGF, transforming growth factor; GABA, gamma-aminobutyric acid; ECM, extracellular matrix.
The miR-874-3p mimic significantly reduced the average amount of LC3 puncta in the rapamycin group compared to the inhibitor [ Figure 7 , p = 0.001] and negative control [ Figure 7 , p = 0006] groups. There was no significant difference seen between treatments in the untreated control group [ Figure 7 , p > 0.05]. This demonstrates in vitro the inhibitory effect of increased miR-874-3p expression on autophagy.
Discussion
Susceptibility genes discovered through GWAS underline pathways that are mechanistically important in IBD. For example, the strong association of the ATG16L1 gene with CD implicates dysregulation of autophagy in these individuals, in particular the selective form of autophagy mediating the clearance of intracellular pathogens [xenophagy]. 4, 26, 37 Similarly, another susceptibility gene SMAD3 is involved in immune function regulation via the TGF-beta pathway. 32, 34, 35 There is evidence that defects in TGF-beta signalling result in uncontrolled inflammation in IBD. 30 Thus, investigating genetic susceptibility associations can point to mechanistically important pathways in IBD for subsequent functional studies and therapeutic targeting. Differential miRNA expression may contribute to the pathogenesis of IBD in several ways. One example is if a polymorphism exists in the binding site of the target mRNA, as demonstrated by Brest et al. 38 Their investigation found miR-196 is upregulated in patients with CD, and the risk variant of the CD susceptibility gene immunity related GTPase M [IRGM] contains a polymorphism in the binding site for miR-196. Consequently, the aberrantly expressed miR-196 downregulates the protective variant of IRGM, but not the risk allele. This altered miR196-IRGM interaction deregulates xenophagy, which is disrupted in CD. 38 We performed a high-throughput miRNA screen in human PBMCs from individuals in a carefully phenotyped IBD cohort and healthy control subjects. A vast portion of miRNAs differentially expressed across the three broad phenotypes of CD, UC and control subjects were driven by the CD group, which included a clinically mixed population of patients [ Table 1, Supplementary table 2] . Interestingly, there were no differentially expressed probes in the UC vs HC comparison. Because the UC group had a mixed population of disease activity as well, in addition to a large number of medication users [5-ASAs], we performed a supplementary non-parametric pairwise analysis stratifying these patients based on activity and 5-ASA use, and still found no miRNAs statistically significant across the groups after correction for multiple testing [Supplementary Table 3] . It remains possible that medication may be contributing to not seeing differential expression compared to healthy controls, and also possible that the subset of cell types analysed could be confounding a significant result.
IBD is not a single entity, but rather a spectrum of disorders sharing clinical features, yet also possessing genetic and phenotypic heterogeneity. Molecular characterization of carefully phenotyped and stratified patients can provide insight into underlying mechanisms driving differences in disease susceptibility and clinical course. To this end, one strength of our study was the large total sample size allowing for investigation of transcriptional mechanisms of IBD in more homogeneous subgroups, by stratifying based on disease activity and location.
We identified a panel of ten miRNAs differentially expressed in CD patients in endoscopic remission compared to healthy control subjects, namely miR-4448, miR-548g-3p, miR-4536-5p, miR-30a-3p, miR-548q, miR-4461, miR-133a-3p, miR-597-5p, miR-619-3p and miR-644a. miR-4448 was the most differentially expressed miRNA in this comparison. Several biological roles for miR-4448 have been identified, including a tumour suppressor effect in human cancer cells 39 and the targeting of SMAD1 and SMAD4 transcripts in mesenchymal stem cells inducing osteoblast differentiation. 40 Our bioinformatic analysis predicted that miR-4448 might target the CD-associated risk gene SMAD3. SMAD3 is a critical component of the TGF-beta pathway and previous studies have found that defects in TGF-beta signalling result in uncontrolled inflammation in IBD 30 and that disruption of SMAD3 impairs TGF-beta-mediated mucosal immunity. 35 Additionally, Monteleone et al. 32 demonstrated that although TGF-beta is upregulated in the mucosa of IBD patients, its immunosuppressive effects in the gut are compromised by downstream perturbations, namely a decrease of Smad3 phosphorylation through inhibition by increased expression of Smad7. 32 Importantly, this inhibition of Smad3 by Smad7 is reversible, as silencing Smad7 restored phosphorylated Smad3 expression and normal TGF-beta signalling. 32 Manipulating the TGF-beta pathway has thus emerged as an attractive therapeutic target in IBD. 34, [41] [42] [43] Findings from our study suggest that the aberrant expression of endogenous miR-4448 in quiescent disease compared to healthy controls is yet another mechanism by which TGF signalling via SMAD3 may be disrupted and may be associated with increased disease susceptibility and transcriptional control of immunity.
In our analysis comparing groups with different disease at the same location, CCD or UC, we identified a panel of seven miRNAs significantly upregulated in CCD compared to UC: miR-874-3p, miR-933, miR-129-5p, miR-1909-3p, miR-212-3p, miR-885-5p and miR-619-3p. Pathway analysis utilizing these seven miRNAs revealed that the majority of miRNAs differentially expressed putatively target many regulatory genes in the autophagy pathway, suggesting miRNA-mediated dysregulation of autophagy in CCD vs UC.
To date, four genetic variants associated with autophagy have been shown to confer risk to CD, but not UC: ATG16L1, IRGM, LRRK2 and NOD2. 4, 26, 27, 44 Furthermore, other genetic variants involved in components of the autophagy pathway have been associated with IBD, such as ULK1. 45, 46 Because autophagy plays a vast number of roles in inflammation and metabolism, a defect in Table 4 . mRNA expression of bioinformatically predicted targets of differentially expressed miRNAs. Differentially expressed mRNA levels in blood for CCD [n = 11] vs UC [N = 41] for bioinformatically predicted targets of differentially expressed miRNAs [ Figure 4 ]. All predicted targets were obtained from miRWalk 2.0, and filtered to be Crohn's disease susceptibility genes. Expression levels were obtained from unpublished RNA-seq data from an ongoing study in our group. Only putative targets with expression directionality inverse to miRNA expression were reported based on biological relevance. Significance at p < 0.05. autophagy can have multiple deleterious consequences relevant in IBD. 47, 48 For example, a recent study found that the inflamed tissue of CD patients carrying the ATG16L1 risk allele demonstrated impaired clearance of certain bacteria compared to inflamed tissue from patients carrying the protective allele. 49 This same study also showed that monocytes from the peripheral blood of CD patients carrying the ATG16L1 risk allele demonstrated dysfunctional killing of a bacterial pathogen. 49 This defect in xenophagy had been previously implicated via the CD-associated ATG16L1 variant in cell culture. 37 Furthermore, the Atg16l1 protein can affect proinflammatory cytokine production, as evidenced by macrophages deficient in Atg16l1 which show high production of the inflammatory cytokines IL-1beta and IL-18 after stimulation with an endotoxin. 50 A defect in autophagy could therefore be a possible mechanism for the aberrant inflammatory response seen in IBD.
The most differentially expressed miRNA in our panel of miRNAs differentially expressed between CCD and UC was miR-874-3p. Our in silico analysis predicted that miR-874-3p targets ATG16L1, an autophagy-related gene strongly associated with genetic susceptibility in individuals with CD. In this study, we conducted in vitro experiments that confirm that miR-874-3p binds to the 3′UTR of ATG16L1 and represses its expression [ Figure 6 ]. We further confirmed that increased expression of miR-874-3p reduces LC3 puncta in rapamycin-treated cells, which demonstrates miR-874-3p dysregulates autophagy in vitro [ Figure 7 ]. Several studies have implicated miR-874-3p in human health and disease. For example, miR-874-3p has been shown to inhibit growth of the SKBR3 breast cancer cell line, 51 as well as have tumour suppressive properties in head and neck squamous cell carcinoma through targeting of histone deacetylase 1 [HDAC1]. 52, 53 Interestingly, increased levels of miR-874-3p suppressing HDAC1 were also shown to positively regulate osteoblast differentiation and mineralization, increasing bone strength during Table 5 . GO BP pathways containing terms related to autophagy predicted to be targeted by differentially expressed miRNAs.
In silico analysis was done using miRWalk 2.0. Reported pathways included terms autophagic, autophagy or macroautophagy. Significance at FDR-adjusted p-value < 0.05. weaning in mice. 54 This was shown both in vivo and with ex vivo cultures of bone marrow cells using an agomir [mimic] of miR-874-3p, suggesting the possible therapeutic use of an miR-874-3p agomir in various pathophysiological contexts. 54 Furthermore, expression profiling of thyroid cancer samples sequenced in The Cancer Genome Atlas found miR-874-3p to be associated with human papillary thyroid cancer and putatively regulates integrin beta 4 [ITGB4]. 55 These studies highlight several roles of miR-874-3p and its targets, but to our knowledge our study is the first to reveal an association of miR-874-3p with autophagy in the context of intestinal inflammation.
miRNAs have the potential to serve as excellent non-invasive biomarkers due to their marked stability in blood. 11 Differentially expressed miRNAs could be used to classify clinical phenotypes, identify pathways that distinguish the onset of UC from CD, stratify risk for aggressive disease behaviour and allow for more individualized treatment planning. One challenge in IBD where there is a need for better biomarkers in particular is in differential diagnosis of colonic IBD where the inflammation in both CD and UC is localized to the colon. Differential diagnosis in this context has important clinical implications especially in relation to decision-making around surgical management or management strategies after colectomy. There is no gold standard for differential diagnosis in colonic IBD, and it is estimated that 10% of these patients will be diagnosed with IBDU. 56 Best current practice often relies on expert examination of symptom profile, serological markers, presence of complications of disease, and invasive endoscopic and/or histopathological assessment to make a diagnosis; yet, even with this multifaceted approach there remains a wide spectrum of variability. 56 Given modern disease-driven treatment strategies and the availability of molecularly targeted therapeutics, having more information about the molecular profile of these patients in a minimally invasive manner may help accurately classify disease, aid in the determination of the treatment protocol as well as predict prognosis and treatment success. Due to the strong association with CCD we tested the potential of miR-874-3p expression to classify individuals diagnosed with CCD vs UC. We showed that miR-874-3p performed extremely well in classifying individuals diagnosed with CCD vs UC [ Figure 5 ]. We confirmed through multivariate linear regression that this difference was not due to cellular populations in the blood samples [Supplementary Table 1] .
While this result is promising, its clinical utility requires validation in a larger cohort of challenging diagnostic cases, including IBDU patients.
A main strength of this study is the careful phenotyping of our cohort to allow for stratification of patients based on disease activity and location. One limitation, however, is the small sample size once stratified into the comparative outcome groups. This would be most important in addressing for the validation of our ROC analysis.
In conclusion, we have identified unique PBMC-derived miRNA signatures differentially expressed in distinct IBD phenotypes, revealing molecular differences in an endoscopically inactive CD population compared to healthy controls as well as CCD compared to UC subjects. These data may provide mechanistic insight into molecular pathways in CD independent of active inflammation, possibly involving autophagy and TGF-beta signalling pathways. These findings may also aid with individualization of patient care through identification of novel diagnostic and therapeutic targets.
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